Application Note: Multiplexed screening of drug-induced mitochondrial dysfunction and cytotoxicity
20 January 2020
Impaired mitochondrial function has been identified as a significant contributor to drug-induced toxicity and has been implicated in late-stage drug failure, black box warnings, and market withdrawal. In this application note, Agilent Cell Analysis assesses the feasibility of combining cytotoxicity and mitochondrial function measurements into a single, multiplexed ‘mix-and-measure’ assay, thereby simplifying screening workflows. Here, the utility of this multiplexed approach to better delineate drug-induced mitochondrial dysfunction and non-specific toxicity after longer-term compound treatments is also examined.